Suppr超能文献

包被阳离子脂质纳米颗粒包载 miR-660 抑制患者来源异种移植肺癌模型中的肿瘤生长。

Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models.

机构信息

Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Laboratory of Experimental Therapy in Oncology, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

出版信息

J Control Release. 2019 Aug 28;308:44-56. doi: 10.1016/j.jconrel.2019.07.006. Epub 2019 Jul 9.

Abstract

Lung cancer is the leading cause of cancer-related deaths. Late diagnosis and inadequate therapies contribute to poor outcomes. MicroRNAs (miRNAs) are small non-coding RNAs and are involved in lung cancer development. Because miRNAs simultaneously regulate several cancer-related genes, they represent an interesting therapeutic approach for cancer treatment. We have developed Coated Cationic Lipid-nanoparticles entrapping miR-660 (CCL660) and intraperitoneally administered (1.5 mg/Kg) twice a week for four weeks into SCID mice carrying subcutaneously lung cancer Patients Derived Xenografts (PDXs). Obtained data demonstrated that miR-660 is down-regulated in lung cancer patients and that its replacement inhibited lung cancer growth by inhibiting the MDM2-P53 axis. Furthermore, systemic delivery of CCL660 increased miRNA levels in tumors and significantly reduced tumor growth in two different P53 wild-type PDXs without off-target effects. MiR-660 administration reduced cancer cells proliferation by inhibiting MDM2 and restoring P53 function and its downstream effectors such as p21. Interestingly, anti-tumoral effects of CCL660 also in P53 mutant PDXs but with a functional p21 pathway were observed. Stable miR-660 expression inhibited the capacity of H460 metastatic lung cancer cells to form lung nodules when injected intravenously into SCID mice suggesting a potential role of miR-660 in metastatic dissemination. To investigate the potential toxic effects of both miRNAs and delivery agents, an in vitro approach revealed that miR-660 replacement did not induce any changes in both mouse and human normal cells. Interestingly, lipid-nanoparticle delivery of synthetic miR-660 had no immunological off-target or acute/chronic toxic effects on immunocompetent mice. Altogether, our results highlight the potential role of coated cationic lipid-nanoparticles entrapping miR-660 in lung cancer treatment without inducing immune-related toxic effects.

摘要

肺癌是癌症相关死亡的主要原因。晚期诊断和治疗不足导致预后不良。微小 RNA(miRNA)是小的非编码 RNA,参与肺癌的发生发展。由于 miRNA 同时调节多个癌症相关基因,因此它们代表了癌症治疗的一种有趣的治疗方法。我们开发了包被阳离子脂质体纳米颗粒包封 miR-660(CCL660),并以 1.5mg/Kg 的剂量每周两次腹腔内给药,持续四周,用于携带皮下肺癌患者衍生异种移植(PDXs)的 SCID 小鼠。获得的数据表明,miR-660 在肺癌患者中下调,其替代物通过抑制 MDM2-P53 轴抑制肺癌生长。此外,CCL660 的系统给药增加了肿瘤中的 miRNA 水平,并在两种不同的 P53 野生型 PDX 中显著减少了肿瘤生长,而没有脱靶效应。miR-660 通过抑制 MDM2 和恢复 P53 功能及其下游效应物如 p21 来抑制癌细胞增殖。有趣的是,在 P53 突变型 PDX 中也观察到了 CCL660 的抗肿瘤作用,但 p21 途径具有功能。稳定的 miR-660 表达抑制了 H460 转移性肺癌细胞在静脉注射到 SCID 小鼠中形成肺结节的能力,这表明 miR-660 在转移扩散中可能发挥作用。为了研究 miRNA 和递药载体的潜在毒性作用,体外方法表明 miR-660 替代物不会引起小鼠和人正常细胞的任何变化。有趣的是,脂质纳米颗粒递送合成 miR-660 对免疫功能正常的小鼠没有免疫相关的脱靶或急性/慢性毒性作用。总之,我们的研究结果强调了包被阳离子脂质体纳米颗粒包封 miR-660 在肺癌治疗中的潜在作用,而不会引起免疫相关的毒性作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验